Ingalls & Snyder LLC Lowers Stake in DURECT Co. (NASDAQ:DRRX)

Ingalls & Snyder LLC trimmed its position in DURECT Co. (NASDAQ:DRRX) by 19.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,590,855 shares of the specialty pharmaceutical company’s stock after selling 393,767 shares during the quarter. Ingalls & Snyder LLC owned 5.13% of DURECT worth $1,193,000 at the end of the most recent quarter.

Separately, Geode Capital Management LLC lifted its position in DURECT by 4.8% during the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after buying an additional 14,658 shares in the last quarter. Institutional investors own 28.03% of the company’s stock.

DURECT Trading Up 0.3 %

Shares of DRRX stock opened at $0.75 on Friday. DURECT Co. has a twelve month low of $0.70 and a twelve month high of $1.88. The company has a market capitalization of $23.28 million, a PE ratio of -1.23 and a beta of 0.91. The firm has a fifty day simple moving average of $0.83 and a 200-day simple moving average of $1.14.

Analysts Set New Price Targets

Several research firms have recently issued reports on DRRX. HC Wainwright reissued a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th. StockNews.com began coverage on DURECT in a report on Friday, February 7th. They issued a “sell” rating for the company.

DURECT Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.